Using Sitagliptin as a Treatment to Prevent New Onset Diabetes After Kidney Transplantation

• Status: Terminated
• Trial end date: 2010-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is designed to see if the use of the drug Sitagliptin (used to reduce insulin resistance) will delay or prevent kidney transplant patients from getting diabetes.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Nebraska
• Treatments: Sitagliptin Phosphate

Criteria

Inclusion Criteria:

• Recipient of a kidney transplant at UNMC, including cadaveric or living donor transplant.

Exclusion Criteria:

• A previous diagnosis of diabetes or previous criteria for diabetes, according to the American Diabetes Association, not previously recognized as diabetes.

• Simultaneous transplant of another solid organ, such liver or heart.

• Patient unable to take oral medication.

• Patient unable to give informed consent.

• Hypersensitivity to sitagliptin.